Robot-assisted Partial Nephrectomy for Hilar and Nonhilar Renal Masses: Comparison of Perioperative, Oncological, and Functional Results in a Multicentre Prospective Cohort (NEPRAH Study, UroCCR 175).

IF 8.3 1区 医学 Q1 ONCOLOGY
European urology oncology Pub Date : 2024-12-01 Epub Date: 2024-06-26 DOI:10.1016/j.euo.2024.06.003
Julien Sarkis, Cecile M Champy, Nicolas Doumerc, Franck Bruyere, Morgan Rouprêt, Nicolas Branger, Louis Surlemont, Constance Michel, Thibaut Waeckel, Bastien Parier, Jean-Baptiste Beauval, Pierre Bigot, Hervé Lang, Maxime Vallee, Julien Guillotreau, Jean-Jacques Patard, Clément Sarrazin, Stéphane de Vergie, Olivier Belas, Romain Boissier, Richard Mallet, Frédéric Panthier, Fayek Taha, Quentin-Côme Le Clerc, Lionel Hoquetis, François Audenet, Louis Vignot, Philippe Paparel, Alexis Fontenil, Jean-Christophe Bernhard, Alexandre Ingels
{"title":"Robot-assisted Partial Nephrectomy for Hilar and Nonhilar Renal Masses: Comparison of Perioperative, Oncological, and Functional Results in a Multicentre Prospective Cohort (NEPRAH Study, UroCCR 175).","authors":"Julien Sarkis, Cecile M Champy, Nicolas Doumerc, Franck Bruyere, Morgan Rouprêt, Nicolas Branger, Louis Surlemont, Constance Michel, Thibaut Waeckel, Bastien Parier, Jean-Baptiste Beauval, Pierre Bigot, Hervé Lang, Maxime Vallee, Julien Guillotreau, Jean-Jacques Patard, Clément Sarrazin, Stéphane de Vergie, Olivier Belas, Romain Boissier, Richard Mallet, Frédéric Panthier, Fayek Taha, Quentin-Côme Le Clerc, Lionel Hoquetis, François Audenet, Louis Vignot, Philippe Paparel, Alexis Fontenil, Jean-Christophe Bernhard, Alexandre Ingels","doi":"10.1016/j.euo.2024.06.003","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>A hilar location for a renal tumour is sometimes viewed as a limiting factor for safe partial nephrectomy. Our aim was to evaluate perioperative, oncological, and functional outcomes of robot-assisted partial nephrectomy (RAPN) for hilar tumours (RAPN-H) in comparison to RAPN for nonhilar tumours (RAPN-NH).</p><p><strong>Methods: </strong>We conducted an observational, multicentre cohort study using prospectively collected data from the French Research Network on Kidney Cancer (UroCCR). The registry includes data for 3551 patients who underwent RAPN for localised or locally advanced renal masses between 2010 and 2023 in 29 hospitals in France. We studied the impact of a hilar location on surgery, postoperative renal function, tumour characteristics, and survival. We also compared rates of trifecta achievement (warm ischaemia time [WIT] <25 min, negative surgical margins, and no perioperative complications) between the groups. Finally, we performed a subgroup analysis of RAPN without vascular clamping. Variables were compared in univariable analysis and using multivariable linear, logistic, and Cox proportional-hazards models adjusted for relevant patient and tumour covariates.</p><p><strong>Key findings and limitations: </strong>The analytical population included 3451 patients, of whom 2773 underwent RAPN-NH and 678 underwent RAPN-H. Longer WIT (β = 2.4 min; p < 0.01), longer operative time (β = 11.4 min; p < 0.01) and a higher risk of postoperative complications (odds ratio 1.33; p = 0.05) were observed in the hilar group. Blood loss, the perioperative transfusion rate, postoperative changes in the estimated glomerular filtration rate, and trifecta achievement rates were comparable between the groups (p > 0.05). At mean follow-up of 31.9 mo, there was no significant difference in recurrence-free survival (hazard ratio [HR] 0.82, 95% confidence interval [CI] 0.58-1.2; p = 0.3), cancer-specific survival (HR 1.1, 95% CI 0.48-2.6; p = 0.79), or overall survival (HR 0.89, 95% CI 0.52-1.53; p = 0.69).</p><p><strong>Conclusions and clinical implications: </strong>Patient and tumour characteristics rather than just hilar location should be the main determinants of the optimal surgical strategy for hilar tumours.</p><p><strong>Patient summary: </strong>We found that kidney tumours located close to major kidney blood vessels led to a longer operation and a higher risk of complications during robot-assisted surgery to remove the tumour. However, tumours in these locations were not related to a higher risk of kidney function loss, cancer recurrence, or death.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":"1487-1496"},"PeriodicalIF":8.3000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European urology oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.euo.2024.06.003","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/26 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objective: A hilar location for a renal tumour is sometimes viewed as a limiting factor for safe partial nephrectomy. Our aim was to evaluate perioperative, oncological, and functional outcomes of robot-assisted partial nephrectomy (RAPN) for hilar tumours (RAPN-H) in comparison to RAPN for nonhilar tumours (RAPN-NH).

Methods: We conducted an observational, multicentre cohort study using prospectively collected data from the French Research Network on Kidney Cancer (UroCCR). The registry includes data for 3551 patients who underwent RAPN for localised or locally advanced renal masses between 2010 and 2023 in 29 hospitals in France. We studied the impact of a hilar location on surgery, postoperative renal function, tumour characteristics, and survival. We also compared rates of trifecta achievement (warm ischaemia time [WIT] <25 min, negative surgical margins, and no perioperative complications) between the groups. Finally, we performed a subgroup analysis of RAPN without vascular clamping. Variables were compared in univariable analysis and using multivariable linear, logistic, and Cox proportional-hazards models adjusted for relevant patient and tumour covariates.

Key findings and limitations: The analytical population included 3451 patients, of whom 2773 underwent RAPN-NH and 678 underwent RAPN-H. Longer WIT (β = 2.4 min; p < 0.01), longer operative time (β = 11.4 min; p < 0.01) and a higher risk of postoperative complications (odds ratio 1.33; p = 0.05) were observed in the hilar group. Blood loss, the perioperative transfusion rate, postoperative changes in the estimated glomerular filtration rate, and trifecta achievement rates were comparable between the groups (p > 0.05). At mean follow-up of 31.9 mo, there was no significant difference in recurrence-free survival (hazard ratio [HR] 0.82, 95% confidence interval [CI] 0.58-1.2; p = 0.3), cancer-specific survival (HR 1.1, 95% CI 0.48-2.6; p = 0.79), or overall survival (HR 0.89, 95% CI 0.52-1.53; p = 0.69).

Conclusions and clinical implications: Patient and tumour characteristics rather than just hilar location should be the main determinants of the optimal surgical strategy for hilar tumours.

Patient summary: We found that kidney tumours located close to major kidney blood vessels led to a longer operation and a higher risk of complications during robot-assisted surgery to remove the tumour. However, tumours in these locations were not related to a higher risk of kidney function loss, cancer recurrence, or death.

机器人辅助肾部分切除术治疗肾门肿块和非肾门肿块:多中心前瞻性队列围手术期、肿瘤学和功能结果比较(NEPRAH 研究,UroCCR 175)。
背景和目的:肾肿瘤位于肾门有时被视为肾部分切除术安全性的限制因素。我们的目的是评估肾门部肿瘤机器人辅助肾部分切除术(RAPN-H)与非肾门部肿瘤机器人辅助肾部分切除术(RAPN-NH)的围术期、肿瘤学和功能性结果:我们利用从法国肾癌研究网络(UroCCR)收集的前瞻性数据开展了一项多中心队列观察研究。该登记册包括2010年至2023年期间在法国29家医院接受RAPN治疗局部或局部晚期肾肿块的3551名患者的数据。我们研究了肾门位置对手术、术后肾功能、肿瘤特征和生存期的影响。我们还比较了三连胜的实现率(温缺血时间[WIT] 主要发现和局限性:分析对象包括3451名患者,其中2773人接受了RAPN-NH手术,678人接受了RAPN-H手术。WIT 更长(β = 2.4 分钟;P 0.05)。在平均31.9个月的随访中,无复发生存率(危险比[HR] 0.82,95% 置信区间[CI] 0.58-1.2;P = 0.3)、癌症特异性生存率(HR 1.1,95% CI 0.48-2.6;P = 0.79)或总生存率(HR 0.89,95% CI 0.52-1.53;P = 0.69)均无显著差异:患者总结:我们发现,靠近肾脏主要血管的肾脏肿瘤导致机器人辅助手术切除肿瘤的手术时间更长,并发症风险更高。然而,位于这些位置的肿瘤与肾功能丧失、癌症复发或死亡的更高风险无关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
15.50
自引率
2.40%
发文量
128
审稿时长
20 days
期刊介绍: Journal Name: European Urology Oncology Affiliation: Official Journal of the European Association of Urology Focus: First official publication of the EAU fully devoted to the study of genitourinary malignancies Aims to deliver high-quality research Content: Includes original articles, opinion piece editorials, and invited reviews Covers clinical, basic, and translational research Publication Frequency: Six times a year in electronic format
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信